Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label multicenter study of SHR2554 tablets in combination with other antitumor therapies for non-small cell lung cancer
CTR20253683Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zeprumetostat in non-small cell lung cancer (NSCLC), sponsored by Hengrui Therapeutics. Primary endpoints: Dose-limiting toxicity, Adverse events and serious adverse events and 1 more. Started Sep 2025; status: active.
02
Drugs
zeprumetostat
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20253683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253683.